Chang-seng Liang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2551571/publications.pdf

Version: 2024-02-01

94433 71685 5,883 92 37 76 citations g-index h-index papers 92 92 92 4382 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Galectinâ€3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients. Journal of the American Heart Association, 2019, 8, e011100.	3.7	19
2	Impaired Right Ventricular Hemodynamics Indicate Preclinical Pulmonary Hypertension in Patients With Metabolic Syndrome. Journal of the American Heart Association, 2015, 4, e001597.	3.7	34
3	Preclinical Systolic and Diastolic Dysfunctions in Metabolically Healthy and Unhealthy Obese Individuals. Circulation: Heart Failure, 2015, 8, 897-904.	3.9	64
4	Preclinical Left Ventricular Diastolic Dysfunction in Metabolic Syndrome. American Journal of Cardiology, 2014, 114, 838-842.	1.6	46
5	Relationship of Plasma Galectinâ€3 to Renal Function in Patients With Heart Failure: Effects of Clinical Status, Pathophysiology of Heart Failure, and Presence or Absence of Heart Failure. Journal of the American Heart Association, 2012, 1, e000760.	3.7	105
6	Oxidative and Nitrosative Stress in Heart Failure. , 2011, , 185-197.		0
7	Increasing Post-Myocardial Infarction Heart Failure Incidence in Elderly Patients. Journal of the American College of Cardiology, 2009, 53, 21-23.	2.8	14
8	Adoptive passive transfer of rabbit \hat{l}^21 -adrenoceptor peptide immune cardiomyopathy into the Rag $2\hat{a}$ °/ \hat{a} ° mouse: Participation of the ER stress. Journal of Molecular and Cellular Cardiology, 2008, 44, 304-314.	1.9	27
9	Darbepoetin alfa exerts a cardioprotective effect in autoimmune cardiomyopathy via reduction of ER stress and activation of the PI3K/Akt and STAT3 pathways. Journal of Molecular and Cellular Cardiology, 2008, 45, 250-260.	1.9	46
10	Pro-apoptotic effects of anti- \hat{l}^2 (sub>1-adrenergic receptor antibodies in cultured rat cardiomyocytes: Actions on endoplasmic reticulum and the prosurvival PI3K-Akt pathway. Autoimmunity, 2008, 41, 434-441.	2.6	16
11	ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1956-H1965.	3.2	225
12	Cardiomyocyte apoptosis in autoimmune cardiomyopathy: mediated via endoplasmic reticulum stress and exaggerated by norepinephrine. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1636-H1645.	3.2	69
13	Cardiac sympathetic nerve terminal function in congestive heart failure. Acta Pharmacologica Sinica, 2007, 28, 921-927.	6.1	32
14	Norepinephrine-induced oxidative stress causes PC-12 cell apoptosis by both endoplasmic reticulum stress and mitochondrial intrinsic pathway: inhibition of phosphatidylinositol 3-kinase survival pathway. American Journal of Physiology - Cell Physiology, 2006, 290, C1373-C1384.	4.6	40
15	Cardiac sympathetic neuroprotective effect of desipramine in tachycardia-induced cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H995-H1003.	3.2	6
16	Norepinephrine induces endoplasmic reticulum stress and downregulation of norepinephrine transporter density in PC12 cells via oxidative stress. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H2381-H2389.	3.2	37
17	Progressive left ventricular remodeling, myocyte apoptosis, and protein signaling cascades after myocardial infarction in rabbits. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1740, 499-513.	3.8	40
18	Extracellular norepinephrine reduces neuronal uptake of norepinephrine by oxidative stress in PC12 cells. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H29-H39.	3.2	29

#	Article	IF	CITATIONS
19	Importance of antioxidant and antiapoptotic effects of \hat{l}^2 -receptor blockers in heart failure therapy. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H1003-H1012.	3.2	64
20	Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function. European Journal of Pharmacology, 2003, 461, 149-158.	3.5	36
21	Sympatholysis and cardiac sympathetic nerve function in the treatment of congestive heart failure**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology Journal of the American College of Cardiology, 2003, 42, 549-551.	2.8	6
22	Desipramine attenuates loss of cardiac sympathetic neurotransmitters produced by congestive heart failure and NE infusion. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H1729-H1736.	3.2	13
23	Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: association with changes in MAPK pathways. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H822-H832.	3.2	86
24	Cardioselective overexpression of HO-1 prevents I/R-induced cardiac dysfunction and apoptosis. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H688-H694.	3.2	119
25	Loss of cardiac sympathetic neurotransmitters in heart failure and NE infusion is associated with reduced NGF. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H363-H371.	3.2	69
26	Differential pre- and postsynaptic effects of desipramine on cardiac sympathetic nerve terminals in RHF. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H1863-H1872.	3.2	6
27	Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. American Journal of Cardiology, 2002, 89, 216-221.	1.6	50
28	Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. Journal of the American College of Cardiology, 2001, 38, 1734-1740.	2.8	88
29	Recurrent coronary events are not increased in postinfarction patients with methylenetetrahydrofolate reductase gene C677T polymorphism. American Journal of Cardiology, 2001, 87, 1289-1292.	1.6	5
30	Effect of smoking on lipid and thrombogenic factors two months after acute myocardial infarction. American Journal of Cardiology, 2000, 86, 813-818.	1.6	15
31	Alterations in cardiac adrenergic terminal function and \hat{l}^2 -adrenoceptor density in pacing-induced heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 278, H1708-H1716.	3.2	44
32	Selegiline improves cardiac sympathetic terminal function and \hat{l}^2 -adrenergic responsiveness in heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H1283-H1290.	3.2	7
33	Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H3012-H3019.	3.2	19
34	Alterations by Norepinephrine of Cardiac Sympathetic Nerve Terminal Function and Myocardial \hat{l}^2 -Adrenergic Receptor Sensitivity in the Ferret. Circulation, 2000, 102, 96-103.	1.6	73
35	Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure. New England Journal of Medicine, 2000, 343, 246-253.	27.0	897
36	ACE inhibition improves cardiac NE uptake and attenuates sympathetic nerve terminal abnormalities in heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H1609-H1617.	3.2	18

#	Article	IF	CITATIONS
37	Thrombogenic Factors and Recurrent Coronary Events. Circulation, 1999, 99, 2517-2522.	1.6	253
38	Reappraisal of the Norris score and the prognostic value of left ventricular ejection fraction measurement for in-hospital mortality after acute myocardial infarction. American Journal of Cardiology, 1999, 83, 589-591.	1.6	12
39	Myocardial \hat{l}^2 -adrenoceptor down-regulation by norepinephrine is linked to reduced norepinephrine uptake activity. European Journal of Pharmacology, 1999, 384, 17-24.	3.5	21
40	Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure. Journal of the American College of Cardiology, 1999, 34, 155-162.	2.8	317
41	Effects of dobutamine on ischemic vasodilation of the forearm in patients with severe congestive heart failure. Journal of Cardiac Failure, 1999, 5, 25-30.	1.7	6
42	Chamber-specific Regulation of Heme Oxygenase-1 (Heat Shock Protein 32) in Right-sided Congestive Heart Failure. Journal of Molecular and Cellular Cardiology, 1999, 31, 1581-1589.	1.9	46
43	Altered Sarcoplasmic Reticulum Ca2+ATPase Gene Expression in Congestive Heart Failure: Effect of Chronic Norepinephrine Infusion. Journal of Molecular and Cellular Cardiology, 1998, 30, 175-185.	1.9	22
44	Elevated myocardial interstitial norepinephrine concentration contributes to the regulation of Na+,K+-ATPase in heart failure. European Journal of Pharmacology, 1996, 309, 235-241.	3.5	10
45	Differential changes of myocardial \hat{l}^2 -adrenoceptor subtypes and G-proteins in dogs with right-sided congestive heart failure. European Journal of Pharmacology, 1996, 309, 201-208.	3.5	11
46	Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure. Circulation, 1996, 94, 2793-2799.	1.6	530
47	Dobutamine Effects on Systole and Diastole in Rats With Myocardial Infarction. American Journal of the Medical Sciences, 1995, 309, 5-12.	1.1	3
48	Metabolic control of the circulation: Implications for congestive heart failure. Progress in Cardiovascular Diseases, 1995, 38, 51-66.	3.1	4
49	Neurohumoral variability in left ventricular dysfunction. American Journal of Cardiology, 1995, 75, 354-359.	1.6	9
50	Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. American Journal of Cardiology, 1995, 75, 1151-1157.	1.6	100
51	Acute reversal of pheochromocytomaâ€induced catecholamine cardiomyopathy. Clinical Cardiology, 1995, 18, 421-423.	1.8	60
52	Contraction Band Necrosis. Journal of Cardiovascular Pharmacology, 1994, 24, 694-701.	1.9	7
53	Comparison of Nifedipine gastrointestinal therapeutic system and Atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris. American Journal of Cardiology, 1994, 73, 23-28.	1.6	35
54	Short-term effects of naloxone hemodynamics and baroreflex function in conscious dogs with pacing-induced congestive heart failure. Journal of the American College of Cardiology, 1994, 23, 194-200.	2.8	22

#	Article	IF	CITATIONS
55	Polymorphism of the gene encoding a human minimal potassium ion channel (minK). Gene, 1994, 151, 339-340.	2.2	55
56	Nitroprusside Infusion Improves Arterial Baroreflex Control of Heart Rate in Dogs with Chronic Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 1994, 24, 702-706.	1.9	4
57	Clinical characteristics of patients in Studies of Left Ventricular Dysfunction (SOLVD). American Journal of Cardiology, 1992, 70, 894-900.	1.6	113
58	Characteristics of peak aerobic capacity in symptomatic and asymptomatic subjects with left ventricular dysfunctiona~†. American Journal of Cardiology, 1992, 69, 1207-1211.	1.6	26
59	Pregnancy enhances cardiotoxicity of cocaine: Role of progesterone. Toxicology and Applied Pharmacology, 1992, 113, 30-35.	2.8	27
60	Both cell surface and internalized \hat{l}^2 -adrenoceptors are reduced in the failing myocardium. European Journal of Pharmacology, 1991, 205, 165-169.	3.5	5
61	Beta-adrenergic receptor density correlates with norepinephrine uptake activity in the failing human heart. Journal of the American College of Cardiology, 1991, 17, A176.	2.8	1
62	Acute Hemodynamic Effects of Pinacidil in Hypertensive Patients with and without Propranolol Pretreatment. Journal of Clinical Pharmacology, 1991, 31, 333-341.	2.0	1
63	Comparison of antianginal efficacies and exercise hemodynamic effects of nifedipine and diltiazem in stable angina pectoris. American Journal of Cardiology, 1989, 63, 414-418.	1.6	16
64	Lisinopril for severe congestive heart failure. American Journal of Cardiology, 1989, 63, D8-D11.	1.6	3
65	Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. American Journal of Cardiology, 1989, 63, 567-570.	1.6	8
66	Effects of Pinacidil on Myocardial Blood Flow and Infarct Size After Acute Left Anterior Descending Coronary Artery Occlusion and Reperfusion in Awake Dogs With and Without a Coexisting Left Circumflex Coronary Artery Stenosis. Journal of Cardiovascular Pharmacology, 1989, 14, 747-755.	1.9	25
67	Modulation of hemodynamic effects with a converting enzyme inhibitor: Acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses. American Heart Journal, 1988, 116, 480-488.	2.7	35
68	Antihypertensive Effects of Pinacidil in Patients with and Without Indomethacin Pretreatment. Clinical and Experimental Hypertension, 1988, 10, 411-431.	0.3	8
69	Effects of Milrinone on Systemic Hemodynamics and Regional Circulations in Dogs with Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 1987, 10, 509-516.	1.9	15
70	Alterations in cardiac \hat{l}^2 -adrenoceptor responsiveness and adenylate cyclase system by congestive heart failure in dogs. European Journal of Pharmacology, 1987, 140, 123-132.	3.5	82
71	Hemodynamic and regional blood flow response to milrinone in patients with severe congestive heart failure: A dose-ranging study. American Heart Journal, 1987, 114, 97-105.	2.7	27
72	Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clinical Pharmacology and Therapeutics, 1986, 40, 587-594.	4.7	40

#	Article	IF	CITATIONS
73	Indomethacin attenuates the hypotensive action of hydralazine. Clinical Pharmacology and Therapeutics, 1986, 39, 564-570.	4.7	23
74	Comparison of antianginal efficacy of nifedipine and isosorbide dinitrate in chronic stable angina: A long-term, randomized, double-blind, crossover study. American Journal of Cardiology, 1985, 55, E9-E14.	1.6	15
75	Contrasting effects of dopamine and dobutamine on myocardial release of norepinephrine during acute myocardial infarction International Heart Journal, 1985, 26, 975-984.	0.6	3
76	Nitroprusside infusion in experimental acute myocardial infarction with systemic hypertension: Effects on systemic hemodynamics and regional myocardial blood flows. American Journal of Cardiology, 1984, 53, 1354-1359.	1.6	6
77	Nifedipine in chronic stable angina: A double-blind placebo-controlled crossover trial. American Journal of Cardiology, 1983, 51, 706-711.	1.6	70
78	Randomized withdrawal from nifedipine: Placebo-controlled study in patients with coronary artery spasm. American Heart Journal, 1982, 104, 690-697.	2.7	56
79	Insulin Infusion in Conscious Dogs. Journal of Clinical Investigation, 1982, 69, 1321-1336.	8.2	248
80	Nifedipine Therapy for Coronary-Artery Spasm. New England Journal of Medicine, 1980, 302, 1269-1273.	27.0	439
81	Mineralocorticoid-Induced Hypertension in Patients with Orthostatic Hypotension. New England Journal of Medicine, 1979, 301, 68-73.	27.0	213
82	Effect of Nadolol in Treatment of Hypertension. Journal of Clinical Pharmacology, 1979, 19, 137-147.	2.0	15
83	Conditioning Effects of Chronic Infusions of Dobutamine. Journal of Clinical Investigation, 1979, 64, 613-619.	8.2	55
84	Renin-Angiotensin System Inhibition in Conscious Sodium-Depleted Dogs. Journal of Clinical Investigation, 1978, 61, 874-883.	8.2	74
85	Metabolic Control of the Circulation. Journal of Clinical Investigation, 1978, 62, 1029-1038.	8.2	123
86	Renin-Angiotensin System Inhibition in Conscious Dogs during Acute Hypoxemia. Journal of Clinical Investigation, 1978, 62, 961-970.	8.2	51
87	Effects of Sympathetic Blockade and Splenectomy on Cardiac Output Response to Muscular Work in Dogs. Cardiology, 1977, 62, 21-34.	1.4	2
88	Effects of Arterial Hypoxemia and Splenic Nerve Stimulation on Myocardial Adenosine 3,5'-Monophosphate in Dogs. Pharmacology, 1975, 13, 193-200.	2.2	1
89	The Myocardial Depressant Effect of Beta-Receptor Blocking Agents. Circulation Research, 1974, 35, 272-280.	4.5	22
90	Comparison of Cardiac Output Responses to 2,4-Dinitrophenol-Induced Hypermetabolism and Muscular Work. Journal of Clinical Investigation, 1973, 52, 2283-2292.	8.2	20

#	Article	IF	CITATION
91	Mechanisms Regulating the Cardiac Output Response to Cyanide Infusion, a Model of Hypoxia. Journal of Clinical Investigation, 1973, 52, 3115-3128.	8.2	18
92	Effects of Splenectomy and Beta-Adrenoceptor Blockade on Cardiac Output Response to Acute Hypoxemia. Journal of Clinical Investigation, 1973, 52, 3129-3134.	8.2	6